Publication date: Mar 01, 2025
Acute respiratory failure is the predominant presentation of intensive care unit (ICU) patients with COVID-19, and lung protective strategies are recommended to mitigate additional respiratory complications such as air-leak syndrome. The aim of this study is to investigate the prevalence, type, and timing of air-leak syndrome with regards to associated factors and patient outcome in patients with COVID-19 in ICUs at a large Swedish emergency hospital. This retrospective study included all adult patients admitted to an ICU for COVID-19-related respiratory failure at ScF6dersjukhuset between March 6, 2020, and June 6, 2021. Primary outcomes were proportion of patients diagnosed with air-leak syndrome and its different types of manifestations, and timing of diagnoses in relation to ICU admission and initiation of invasive ventilation. Secondary outcomes included the highest level of respiratory support prior to the diagnosis of air-leak syndrome, patient characteristics and treatment variables associated with air-leak syndrome, and 90-day mortality for patients with air-leak syndrome compared to those without. Out of a total of 669 patients, 81 (12%) were diagnosed with air-leak syndrome. Air-leak syndrome manifested as pneumomediastinum (PMD) (n = 58, 72%), pneumothorax (PTX) (n = 43, 53%), subcutaneous emphysema (SCE) (n = 28, 35%) and pneumatocele (PC) (n = 4, 4. 9%). Air-leak syndrome was diagnosed at a median of 14 days (IQR 6-22) after ICU admission and 12 days (IQR 6-19) following the initiation of invasive ventilation. The highest respiratory support prior to diagnosis was invasive ventilation (IV) in 64 patients (79%), non-invasive ventilation in two patients (2. 5%), and low- or high-flow oxygen in 15 patients (19%). Multiple logistic regression showed that pulmonary disease at baseline (OR 1. 87, 95% CI 1. 07-3. 25), a lower body mass index (OR 0. 95, 95% CI 0. 9-0. 99), admission later compared with earlier in the pandemic (OR 3. 89, 95% CI 2. 14-7. 08), and IV (OR 3. 92, 95% CI 2. 07-7. 44) were associated with an increased risk of air-leak syndrome. Compared with patients not diagnosed with air-leak syndrome, patients with air-leaks had a higher mortality at 90 days after ICU admission, 46% versus 26% (p
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Medical air |
disease | MESH | syndrome |
disease | MESH | COVID-19 |
disease | MESH | respiratory failure |
disease | MESH | complications |
disease | MESH | emergency |
disease | MESH | pneumomediastinum |
disease | MESH | pneumothorax |
disease | MESH | subcutaneous emphysema |
drug | DRUGBANK | Oxygen |
disease | MESH | pulmonary disease |